The COVID-RASi Trial (COVID-19)

NCT04591210 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

372

Enrollment

OTHER

Sponsor class

Conditions

COVID-19
Cardiovascular Diseases

Interventions

DRUG: Angiotensin converting enzyme inhibitor
DRUG: Angiotensin II Receptor Blockers

Sponsor

Ottawa Heart Institute Research Corporation